Cargando…

Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia

BACKGROUND & OBJECTIVE: Interleukin-6 (IL-6) is involved in inflammation and has a significant role in chronic lymphocytic leukemia (CLL) progression. Accordingly, IL-6 level may increase in CLL-affected patients compared to healthy individuals. The -174G>C single nucleotide polymorphism (SNP...

Descripción completa

Detalles Bibliográficos
Autores principales: Rostamzadeh Khameneh, Zakieh, Mohammadian, Mahshid, Eishi Oskuie, Ali, Asghari, Rahim, Nemati, Mohadeseh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Society of Pathology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646739/
https://www.ncbi.nlm.nih.gov/pubmed/38024543
http://dx.doi.org/10.30699/IJP.2023.544600.2790
_version_ 1785134950921535488
author Rostamzadeh Khameneh, Zakieh
Mohammadian, Mahshid
Eishi Oskuie, Ali
Asghari, Rahim
Nemati, Mohadeseh
author_facet Rostamzadeh Khameneh, Zakieh
Mohammadian, Mahshid
Eishi Oskuie, Ali
Asghari, Rahim
Nemati, Mohadeseh
author_sort Rostamzadeh Khameneh, Zakieh
collection PubMed
description BACKGROUND & OBJECTIVE: Interleukin-6 (IL-6) is involved in inflammation and has a significant role in chronic lymphocytic leukemia (CLL) progression. Accordingly, IL-6 level may increase in CLL-affected patients compared to healthy individuals. The -174G>C single nucleotide polymorphism (SNP) in IL-6 promoter region has been related to differences in IL-6 transcription. Therefore, we investigated the possible association of IL-6 polymorphism with CLL. METHODS: We examined the -174G>C SNP in IL-6 gene and studied its possible relationship with CLL in affected patients and in healthy controls using Amplification Refractory Mutation System- polymerase chain reaction genotyping method. IL-6 plasma level was measured in both studied groups. RESULTS: According to the results, IL-6 mean plasma concentration was increased significantly in the CLL patients compared to the controls. However, 174G>C genotype of the IL-6 gene was not associated with CLL. Furthermore, there were no significant differences in the distribution of allele and genotype frequencies between the CLL-affected patients and the controls (P>0.05). CONCLUSION: Our study showed that -174G>C SNP in promotor of IL-6 gene could not be considered a risk factor for CLL. Larger prospective studies should be performed to confirm our results.
format Online
Article
Text
id pubmed-10646739
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Iranian Society of Pathology
record_format MEDLINE/PubMed
spelling pubmed-106467392023-01-01 Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia Rostamzadeh Khameneh, Zakieh Mohammadian, Mahshid Eishi Oskuie, Ali Asghari, Rahim Nemati, Mohadeseh Iran J Pathol Original Article BACKGROUND & OBJECTIVE: Interleukin-6 (IL-6) is involved in inflammation and has a significant role in chronic lymphocytic leukemia (CLL) progression. Accordingly, IL-6 level may increase in CLL-affected patients compared to healthy individuals. The -174G>C single nucleotide polymorphism (SNP) in IL-6 promoter region has been related to differences in IL-6 transcription. Therefore, we investigated the possible association of IL-6 polymorphism with CLL. METHODS: We examined the -174G>C SNP in IL-6 gene and studied its possible relationship with CLL in affected patients and in healthy controls using Amplification Refractory Mutation System- polymerase chain reaction genotyping method. IL-6 plasma level was measured in both studied groups. RESULTS: According to the results, IL-6 mean plasma concentration was increased significantly in the CLL patients compared to the controls. However, 174G>C genotype of the IL-6 gene was not associated with CLL. Furthermore, there were no significant differences in the distribution of allele and genotype frequencies between the CLL-affected patients and the controls (P>0.05). CONCLUSION: Our study showed that -174G>C SNP in promotor of IL-6 gene could not be considered a risk factor for CLL. Larger prospective studies should be performed to confirm our results. Iranian Society of Pathology 2023 2023-10-15 /pmc/articles/PMC10646739/ /pubmed/38024543 http://dx.doi.org/10.30699/IJP.2023.544600.2790 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution- 4.0 International License(https://creativecommons.org/licenses/by/4.0/) which permits Share, copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, even commercially.
spellingShingle Original Article
Rostamzadeh Khameneh, Zakieh
Mohammadian, Mahshid
Eishi Oskuie, Ali
Asghari, Rahim
Nemati, Mohadeseh
Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia
title Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia
title_full Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia
title_fullStr Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia
title_full_unstemmed Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia
title_short Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia
title_sort evaluation the -174g>c genetic polymorphism of interleukin-6 in iranian patients with chronic lymphocytic leukemia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646739/
https://www.ncbi.nlm.nih.gov/pubmed/38024543
http://dx.doi.org/10.30699/IJP.2023.544600.2790
work_keys_str_mv AT rostamzadehkhamenehzakieh evaluationthe174gcgeneticpolymorphismofinterleukin6iniranianpatientswithchroniclymphocyticleukemia
AT mohammadianmahshid evaluationthe174gcgeneticpolymorphismofinterleukin6iniranianpatientswithchroniclymphocyticleukemia
AT eishioskuieali evaluationthe174gcgeneticpolymorphismofinterleukin6iniranianpatientswithchroniclymphocyticleukemia
AT asgharirahim evaluationthe174gcgeneticpolymorphismofinterleukin6iniranianpatientswithchroniclymphocyticleukemia
AT nematimohadeseh evaluationthe174gcgeneticpolymorphismofinterleukin6iniranianpatientswithchroniclymphocyticleukemia